Category Archives: ESC & iPSC

ESC & iPSC News is an online publication and email newsletter dedicated to the latest research in the fields of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).
Subscribe
Since 2007, ESC & iPSC News has been providing weekly updates on the top publications, reviews, and news in pluripotent stem cell research. Through our website, Twitter, and email newsletters, our editorial team is proud to help keep researchers and medical professionals up-to-date with the latest discoveries, jobs, and event postings in the pluripotent stem cell field.

Vulnerability to Shear Stress Caused by Altered Peri-Endothelial Matrix Is a Key Feature of Moyamoya Disease

Hyaluronan synthase 2 was strongly expressed in endothelial progenitor cells in the thickened intima. Moyamoya disease lesions showed minimal staining for chondroitin sulfate and hyaluronan in the endothelium, in contrast to control endothelium showing positive staining for both.
[Scientific Reports]
Matsuo, M., Nadanaka, S., Soga, M., Sugiyama, T., Serigano, S., Shimano, K., Ichinose, F., Nakamura, T., Maeda, T., Houkin, K., Era, T., & Kitagawa, H. (2021). Vulnerability to shear stress caused by altered peri-endothelial matrix is a key feature of Moyamoya disease. Scientific Reports, 11(1), 1552. https://doi.org/10.1038/s41598-021-81282-9 Cite
Full Article
Bookmark

No account yet? Register

0
Share

MicroRNA-494-3p Inhibits Formation of Fast Oxidative Muscle Fibres by Targeting E1A-Binding Protein p300 in Human-Induced Pluripotent Stem Cells

Myogenesis in human induced pluripotent stem cells with the Tet/ON-myogenic differentiation 1 gene was induced by culturing them in doxycycline-supplemented differentiation medium for seven days.
[Scientific Reports]
Iwasaki, H., Ichihara, Y., Morino, K., Lemecha, M., Sugawara, L., Sawano, T., Miake, J., Sakurai, H., Nishi, E., Maegawa, H., & Imamura, T. (2021). MicroRNA-494-3p inhibits formation of fast oxidative muscle fibres by targeting E1A-binding protein p300 in human-induced pluripotent stem cells. Scientific Reports, 11(1), 1161. https://doi.org/10.1038/s41598-020-80742-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

RheinCell Therapeutics Achieves Milestone GMP Certification to Manufacture Cord Blood-Derived iPSCs for Safe and Compliant Cell Therapies

RheinCell Therapeutics GmbH announced it has received Good Manufacturing Practice certification and Manufacturing Authorization. This marks a landmark achievement for RheinCell, which is now among a select few iPSCs manufacturers to have received the critical certification.
[Lifescience Newswire]
Press Release
Bookmark

No account yet? Register

0
Share

PU.1 Drives Specification of Pluripotent Stem Cell-Derived Endothelial Cells to LSEC-Like Cells

Researchers present a computational workflow that could identify transcription factors that were crucial for modulating pathways involved in cell lineage specification.
[Cell Death & Disease]
De Smedt, J., van Os, E. A., Talon, I., Ghosh, S., Toprakhisar, B., Furtado Madeiro Da Costa, R., Zaunz, S., Vazquez, M. A., Boon, R., Baatsen, P., Smout, A., Verhulst, S., van Grunsven, L. A., & Verfaillie, C. M. (2021). PU.1 drives specification of pluripotent stem cell-derived endothelial cells to LSEC-like cells. Cell Death & Disease, 12(1), 1–18. https://doi.org/10.1038/s41419-020-03356-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Great Expectations: Induced Pluripotent Stem Cell Technologies in Neurodevelopmental Impairments

Investigators introduce the development of induced pluripotent stem cells (iPSCs), the currently established iPSCs disease models, and artificial organoids related to neurodevelopmental impairments.
[International Journal of Medical Sciences]
Zhang, X., Li, Z., Liu, Y., & Gai, Z. (2021). Great Expectations: Induced pluripotent stem cell technologies in neurodevelopmental impairments. International Journal of Medical Sciences, 18(2), 459–473. https://doi.org/10.7150/ijms.51842 Cite
Full Article
Bookmark

No account yet? Register

0
Share

The T-Box Transcription Factor Eomesodermin Governs Haemogenic Competence of Yolk Sac Mesodermal Progenitors

Investigators demonstrated using an ESC model that transient expression of the T-box transcription factor Eomesodermin governs haemogenic competency of extra-embryonic mesoderm.
[Nature Cell Biology]
Harland, L. T. G., Simon, C. S., Senft, A. D., Costello, I., Greder, L., Imaz-Rosshandler, I., Göttgens, B., Marioni, J. C., Bikoff, E. K., Porcher, C., de Bruijn, M. F. T. R., & Robertson, E. J. (2021). The T-box transcription factor Eomesodermin governs haemogenic competence of yolk sac mesodermal progenitors. Nature Cell Biology, 23(1), 61–74. https://doi.org/10.1038/s41556-020-00611-8 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Loss of the Fragile X Syndrome Protein FMRP Results in Misregulation of Nonsense-Mediated mRNA Decay

The authors report that FMRP deficiency resulted in hyperactivated nonsense-mediated mRNA decay in human SH-SY5Y neuroblastoma cells and fragile X syndrome fibroblast-derived iPSCs.
[Nature Cell Biology]
Kurosaki, T., Imamachi, N., Pröschel, C., Mitsutomi, S., Nagao, R., Akimitsu, N., & Maquat, L. E. (2021). Loss of the fragile X syndrome protein FMRP results in misregulation of nonsense-mediated mRNA decay. Nature Cell Biology, 23(1), 40–48. https://doi.org/10.1038/s41556-020-00618-1 Cite
Abstract
Bookmark

No account yet? Register

0
Share

An Autophagy Enhancer Ameliorates Diabetes of Human IAPP-Transgenic Mice through Clearance of Amyloidogenic Oligomer

Researchers showed that a recently identified autophagy enhancer (MSL-7) reduces human IAPP oligomer accumulation in human iPSC-derived β-cells and diminishes oligomer-mediated apoptosis of β-cells.
[Nature Communications]
Kim, J., Park, K., Kim, M. J., Lim, H., Kim, K. H., Kim, S.-W., Lee, E.-S., Kim, H. (Henry), Kim, S. J., Hur, K. Y., Kim, J. H., Ahn, J. H., Yoon, K.-H., Kim, J.-W., & Lee, M.-S. (2021). An autophagy enhancer ameliorates diabetes of human IAPP -transgenic mice through clearance of amyloidogenic oligomer. Nature Communications, 12(1), 183. https://doi.org/10.1038/s41467-020-20454-z Cite
Full Article
Bookmark

No account yet? Register

0
Share

The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models

Scientists advocate for a paradigm shift towards the application of human iPSC-derived systems for Alzheimer’s and Parkinson’s disease modeling and the development of improved human-based models in a dish for drug discovery and preclinical assessment of therapeutic targets.
[Molecular Therapy]
MacDougall, G., Brown, L. Y., Kantor, B., & Chiba-Falek, O. (2021). The path to progress preclinical studies of age-related neurodegenerative diseases: A perspective on rodent and hiPSC-derived models. Molecular Therapy, 0(0). https://doi.org/10.1016/j.ymthe.2021.01.001 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Mitochondrial DNA Dynamics in Reprogramming to Pluripotency

The authors examine potential mechanisms for maintenance or shifts in heteroplasmy that occur in iPSCs generated by cellular reprogramming, and further discuss manipulations that can alter heteroplasmy to impact stem and differentiated cell performance.
[Trends in Cell Biology]
Sercel, A. J., Carlson, N. M., Patananan, A. N., & Teitell, M. A. (2021). Mitochondrial DNA Dynamics in Reprogramming to Pluripotency. Trends in Cell Biology, 0(0). https://doi.org/10.1016/j.tcb.2020.12.009 Cite
Full Article
Bookmark

No account yet? Register

0
Share

BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson’s Disease

BlueRock Therapeutics, in collaboration with Memorial Sloan Kettering Cancer Center, announced that the US FDA has cleared their Investigational New Drug application to proceed with a Phase I study in patients with advanced Parkinson’s disease (PD). This is the first trial in the US to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease.
[BlueRock Therapeutics (PR Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share
Share